The interaction of serum folate and estradiol levels in Alzheimer's disease.

OBJECTIVES: In vitro and in vivo animal studies suggest that sex steroids, such as estrogens and testosterone, could protect the brain. However, estrogen replacement therapy (ERT) for Alzheimer's disease (AD) in women has not been successful. We hypothesised that the lack of effect of ERT might...

Full description

Bibliographic Details
Main Authors: Hogervorst, E, Smith, A
Format: Journal article
Language:English
Published: 2002
_version_ 1797075289570803712
author Hogervorst, E
Smith, A
author_facet Hogervorst, E
Smith, A
author_sort Hogervorst, E
collection OXFORD
description OBJECTIVES: In vitro and in vivo animal studies suggest that sex steroids, such as estrogens and testosterone, could protect the brain. However, estrogen replacement therapy (ERT) for Alzheimer's disease (AD) in women has not been successful. We hypothesised that the lack of effect of ERT might be related to an interaction between estrogens and some other factor(s) associated with AD. DESIGN, SETTING AND METHODS: We analysed total estrogen (TE) and testosterone (TT) levels in women diagnosed with AD and controls of the Oxford Project To Investigate Memory and Ageing. Because estradiol (TE2) after the menopause is largely derived from estrone (TE1), we computed the ratio TE2/(TE1+TE2) and a total steroid index (TT+TE2+TE1). RESULTS: Women with AD (n=66) had significantly higher levels of TE2 (27+/-13 vs. 21+/-13) and a higher TE2/(TE1+TE2) ratio. Stepwise logistic regression analyses showed that the TE2/(TE1+TE2) ratio was the main sex steroid predictor for AD (O.R.=1.06, 95% C.I.=1.01-1.11, p<0.01). Multiple regression analyses revealed that dementia severity was associated with an interaction between the TE2/(TE1+TE2) ratio and serum folate (B=4.59 (SE=1.48), beta=1.22, 95% C.I.=1.62-7.56, p<0.005). None of the other potential mediators of this association (body mass index, sex hormone binding globulin, homocysteine levels, ApoE genotype, smoking, diabetes, blood pressure) was significant. MAIN FINDINGS: A high ratio of estradiol to total estrogens is associated with AD but, in subjects with a high ratio, the dementia severity was lower in those with high serum folate levels. CONCLUSIONS: If this association is causal, then supplementation with folic acid might be considered in future studies on ERT in AD.
first_indexed 2024-03-06T23:48:21Z
format Journal article
id oxford-uuid:71be598c-f5b8-4405-b34a-d12f3a16755b
institution University of Oxford
language English
last_indexed 2024-03-06T23:48:21Z
publishDate 2002
record_format dspace
spelling oxford-uuid:71be598c-f5b8-4405-b34a-d12f3a16755b2022-03-26T19:45:36ZThe interaction of serum folate and estradiol levels in Alzheimer's disease.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:71be598c-f5b8-4405-b34a-d12f3a16755bEnglishSymplectic Elements at Oxford2002Hogervorst, ESmith, AOBJECTIVES: In vitro and in vivo animal studies suggest that sex steroids, such as estrogens and testosterone, could protect the brain. However, estrogen replacement therapy (ERT) for Alzheimer's disease (AD) in women has not been successful. We hypothesised that the lack of effect of ERT might be related to an interaction between estrogens and some other factor(s) associated with AD. DESIGN, SETTING AND METHODS: We analysed total estrogen (TE) and testosterone (TT) levels in women diagnosed with AD and controls of the Oxford Project To Investigate Memory and Ageing. Because estradiol (TE2) after the menopause is largely derived from estrone (TE1), we computed the ratio TE2/(TE1+TE2) and a total steroid index (TT+TE2+TE1). RESULTS: Women with AD (n=66) had significantly higher levels of TE2 (27+/-13 vs. 21+/-13) and a higher TE2/(TE1+TE2) ratio. Stepwise logistic regression analyses showed that the TE2/(TE1+TE2) ratio was the main sex steroid predictor for AD (O.R.=1.06, 95% C.I.=1.01-1.11, p<0.01). Multiple regression analyses revealed that dementia severity was associated with an interaction between the TE2/(TE1+TE2) ratio and serum folate (B=4.59 (SE=1.48), beta=1.22, 95% C.I.=1.62-7.56, p<0.005). None of the other potential mediators of this association (body mass index, sex hormone binding globulin, homocysteine levels, ApoE genotype, smoking, diabetes, blood pressure) was significant. MAIN FINDINGS: A high ratio of estradiol to total estrogens is associated with AD but, in subjects with a high ratio, the dementia severity was lower in those with high serum folate levels. CONCLUSIONS: If this association is causal, then supplementation with folic acid might be considered in future studies on ERT in AD.
spellingShingle Hogervorst, E
Smith, A
The interaction of serum folate and estradiol levels in Alzheimer's disease.
title The interaction of serum folate and estradiol levels in Alzheimer's disease.
title_full The interaction of serum folate and estradiol levels in Alzheimer's disease.
title_fullStr The interaction of serum folate and estradiol levels in Alzheimer's disease.
title_full_unstemmed The interaction of serum folate and estradiol levels in Alzheimer's disease.
title_short The interaction of serum folate and estradiol levels in Alzheimer's disease.
title_sort interaction of serum folate and estradiol levels in alzheimer s disease
work_keys_str_mv AT hogervorste theinteractionofserumfolateandestradiollevelsinalzheimersdisease
AT smitha theinteractionofserumfolateandestradiollevelsinalzheimersdisease
AT hogervorste interactionofserumfolateandestradiollevelsinalzheimersdisease
AT smitha interactionofserumfolateandestradiollevelsinalzheimersdisease